Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1701 vs Herceptin plus docetaxel in untreated HER2-positive metastatic breast cancer
CTR20192189Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1701 in breast cancer, sponsored by Qilu Pharmaceutical. Started Dec 2020; status: completed.
02
Drugs
QL1701
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20192189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192189.